Avitinib (maleate dihydrate)
Avitinib (Abivertinib) maleate dihydrate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate dihydrate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate dihydrate shows anticancer effects[1][2].
Product Specifications
CAS Number
1822357-78-7
Product Name Alternative
Abivertinib (maleate dihydrate) ; AC0010 (maleate dihydrate)
UNSPSC
12352005
Target
Apoptosis; Btk; EGFR
Related Pathways
Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=C(C=C)NC1=CC=CC(OC2=NC(NC3=CC(F)=C(N4CCN(C)CC4)C=C3)=NC5=C2C=CN5)=C1.OC(/C=C\C(O)=O)=O.O.O
Molecular Formula
C30H34FN7O8
Molecular Weight
639.63
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD81 / TAPA-1 (1.3.3.22), CF405S conjugate, 0.1mg/mL
CD106 / VCAM1 (VCAM1/843), CF594 conjugate, 0.1mg/mL
CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) (rCD30/412), CF568 conjugate, 0.1mg/mL
